Jim Cramer Says You Should Buy This ‘Strong Buy' Stock ‘Hand Over Fist'
About LLY Stock
Eli Lilly's stock has seen plenty of volatility this year and stands at a loss of 2% in the year to date. The stock is up roughly 3% in the last month but down close to 11% in its past three months. It is also down just under 2% over the past 52 weeks.
Taking a long-term view, the stock has gained 73% in the last two years and nearly 390% in the last five years.
Eli Lilly Miss EPS Estimates
Eli Lilly posted its first-quarter results on May 1. Revenue increased 45% to $12.73 billion, beating analyst estimates of $12.62 billion. However, the company's profit of $3.34 per adjusted share missed analysts' $3.52-per-share estimate.
Sales for Mounjaro came to $3.84 billion, a 113% rise year-over-year, and also beat analysts' $3.75 billion estimate. Zepbound generated $2.31 billion in revenue, also beating analysts' $2.27 billion estimate while recording a 20.9% rise year-over-year. Jardiance grew 48% YoY to $1.01 billion, easily beating analysts' $675 million estimate.
For 2025, management has reiterated its revenue guidance but has lowered its earnings expectations. Revenue is anticipated in a range of $58 billion to $61 billion, reflecting 32% annual growth at the midpoint. Eli Lilly lowered its earnings guidance from a range of $22.50 to $20.78 per share to a range of $22.28 to $20.78 per share.
Jim Cramer on Eli Lilly
Jim Cramer, the Mad Money host, emphasized Eli Lilly's advantage in the weight-loss drug market, especially against rival Novo Nordisk (NVO). The expert pointed out that new data showed Eli Lilly's GLP-1 drug to be significantly better than Novo Nordisk's offering in terms of weight-loss effectiveness.
As per reports, participants who took Eli Lilly's Zepbound lost an average of 50 pounds over 72 weeks, while participants who took Novo Nordisk's Wegovy lost an average of 33 pounds. The key difference in the drug is, that Zepbound targets two hormones, GLP-1 and GIP, on the other hand, Wegovy only targets GLP-1.
Cramer argued that once investors recognize the clear superiority of Eli Lilly's drug, its stock could see a major surge of around 100 points. Thus, he encouraged investors to buy up the stock 'hand over fist' given the company's solid position in the weight-loss market.
Analyst Takes on Eli Lilly
Eli Lilly has always been a favorite on Wall Street, receiving a 'Strong Buy' rating from experts with a mean price target of $992.17, reflecting upside potential of 31% from current prices.
25 analysts have reviewed the stock and given it 21 'Strong Buy' ratings, one 'Moderate Buy' rating, and three 'Hold' ratings.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
27 minutes ago
- National Post
Closure Systems International Launches Defender-Lok™ CRC Product Line
Lightweight. Drop-in. Scalable. Sustainable. Article content INDIANAPOLIS — Closure Systems International (CSI), a global leader in closure design and manufacturing, announces the launch of its new child-resistant closure (CRC) platform: Defender-Lok™. Engineered for OTC and nutraceutical applications, Defender-Lok delivers certified safety, operational efficiency, and sustainability in a drop-in, high-performance solution. Article content Article content Article content Built for Line Efficiency and Compliance Article content Defender-Lok is designed to integrate seamlessly into existing capping and filling lines—minimizing downtime, feeder jams, and sealing failures. The result: optimized production, simplified validation, and consistent throughput. The closures are certified child-resistant and senior-friendly, offering peace of mind to both manufacturers and consumers. Article content 'In the OTC and nutraceutical market, child-resistant closures demonstrate a brand's commitment to consumer safety and regulatory compliance. A well-engineered design meets the expectations of today's health-conscious shoppers, ensures compliance, and integrates seamlessly with high-speed filling and capping lines,' said Chuck Newswanger, Director, Global Commercial Innovation and Technical Development–Pharmaceutical Packaging at CSI. Article content Key features of Defender-Lok include: Article content Sustainability by Design Article content With growing Extended Producer Responsibility (EPR) requirements and state-level mandates like California's SB-54, sustainability is no longer optional. Defender-Lok is designed for material minimization—reducing resin use, shipping weight, and overall environmental impact. Select SKUs already exceed 2027 SB-54 targets, and all closures in the line can be produced using CSI's PolyCycle™ PCR resin, which is made from post-consumer content and fully recyclable. Article content Backed by Global Scale and Technical Expertise Article content CSI brings more than 90 years of experience and operates nine manufacturing sites across the U.S., Mexico, Costa Rica, China, and Japan. All CRC products, including Defender-Lok, are manufactured in FSSC-22000 certified facilities with in-house tooling and R&D support. CSI also offers customers full application assistance, including on-site technical service, validation audits, and commercialization support. Article content Article content Defend Product Integrity – Lok In Performance Article content Article content Article content Article content Article content Contacts Article content Clint S. Rush Director of Marketing & Business Development
Globe and Mail
27 minutes ago
- Globe and Mail
Securities Fraud Investigation Into Novo Nordisk A/S (NVO) Continues – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Novo Nordisk A/S ('Novo Nordisk' or the 'Company') (NYSE: NVO) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NOVO NORDISK A/S (NVO), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims & Hers Health, Inc. ('Hims') and its weight loss drug, Wegovy, would no longer be available through Hims, stating that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' On this news, Novo Nordisk's stock price fell $4.05, or 5.5%, to close at $69.72 per share on June 23, 2025, thereby injuring investors. Then, on July 29, 2025, Novo Nordisk cut its previously issued guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s. On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors further. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Novo Nordisk should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Globe and Mail
27 minutes ago
- Globe and Mail
Chase Celebrates Major Milestone in its Multi-Billion Dollar Retail Expansion
JPMorganChase today celebrated the construction of its 1,000 th branch since launching its market expansion initiative in 2018, marking a significant milestone toward improving access to financial services across the nation. At a ribbon-cutting ceremony in Charlotte, North Carolina, JPMorganChase executives joined local community members to officially open the new branch and highlight the positive impact Chase branches have on local neighborhoods. 'Every day, nearly one million customers visit our branches to manage their finances or get advice on how to save, spend and grow their money,' said Jennifer Roberts, CEO of Chase Consumer Banking. 'We are very proud of the role we play to serve these customers while providing opportunities for long-term economic growth through construction, community investments and local hiring.' Chase will continue expanding its presence in low-to-moderate income and rural communities with limited access to traditional banking services, as well as markets such as Boston, Charlotte, Philadelphia, Raleigh and Washington, D.C. Over the past seven years, Chase has opened more branches than all large bank peers combined, bringing affordable and convenient financial services to communities in all lower 48 states. Today, Chase covers more Americans than any other bank, with 68% of the U.S. population within an accessible drive time to one of its branches. The bank is on track to meet its goal of 500 new branches by early 2027, contributing to its long-term plans of reaching 75% of the national population within an accessible drive and over 50% within each state. Chase Branches: Catalysts for Economic Growth Chase branches are more than just financial service providers; they are vital engines driving economic activity and supporting local communities. JPMorganChase's internal research highlights the substantial impact these branches have on lending, employment, customer engagement and deposit balances. Annually, Chase branches originate billions in business and home loans, directly fueling local lending activity and fostering economic growth in surrounding areas. With a workforce of around 50,000 customer-facing staff, Chase branches offer significant employment opportunities, bolstering the local economy. Chase branches also play a pivotal role in supporting local economic activity and retail spending, serving approximately 300 million visiting customers each year and handling around 900 million transactions. These findings reveal that new branches have stronger retail activity and marked increases in business activity, mortgage originations and household income in areas with Chase branches compared to matched areas without them. "We've long recognized that our branches serve as storefronts for all our capabilities across the firm, from banking to lending to wealth management and business formation," Roberts added. "What's truly exciting is seeing them act as catalysts for economic activity in the communities we serve." When this expansion is completed, Chase will have added more than 1,100 branches, renovated 4,300 locations, entered 80 markets and hired more than 10,500 employees to its Consumer Bank team since 2018. 'Our commitment to local communities extends beyond providing financial services,' said Tom Horne, Head of Consumer Branch Banking at Chase. 'From construction to day-to-day branch operations, we hire locally, ensuring that our expansion directly contributes to the economic vitality of the areas we serve. We're not just building branches; we are investing in the long-term health and future of our communities.' Chase is actively hiring to support these new branches, building on its more than 50,000 local bankers, advisors, business relationship managers and branch managers, who together operate as a local team of experts to serve customer needs. Chase offers $20 – $25 per hour, depending on work location, as minimum base pay for U.S. overtime-eligible employees, as well as a comprehensive benefits package that is valued on average at approximately $19,500 per employee. The bank offers a variety of different branch formats, depending on the specific needs of the community. Some locations include meeting rooms and private spaces for personal conversations, while high-volume, full-service branches feature multiple transaction windows. Chase also operates 19 Community Centers across the country as part of an overall effort to expand access to banking, tools and advice to people who might not otherwise have access to them. These Community Centers are part of Chase's community-inspired branch network, which includes 300 locations in underserved areas. Ramping Up Affluent Offering In addition to the new branches, Chase is expanding its affluent offering by opening new J.P. Morgan Financial Centers in many markets across the country, bringing a highly personalized level of service to millions of potential clients. The bank plans to have 31 Financial Centers open by the end of next year. Today, Chase serves nearly 80 million consumers and close to 6 million small businesses with a broad range of financial services, including personal banking, credit cards, mortgages, auto financing, investment advice, small business loans and payment processing. To check for updates or to learn more about Chase's branches, products and services, please visit About Chase Chase is the U.S. consumer and commercial banking business of JPMorgan Chase & Co. (NYSE: JPM), a leading financial services firm based in the United States of America with assets of $4.6 trillion and operations worldwide. Chase serves more than 85 million consumers and 7 million small businesses, with a broad range of financial services, including personal banking, credit cards, mortgages, auto financing, investment advice, small business loans and payment processing. Customers can choose how and where they want to bank: Nearly 5,000 branches in 48 states and the District of Columbia, nearly 15,000 ATMs, mobile, online and by phone. For more information, go to
